顺铂和氟尿嘧啶交替腹腔灌注并ECF方案治疗原发性腹膜癌疗效观察

Cisplatin and Fluorouracil Alternating Intraperitoneal Perfusion and ECF in Treatment of Primary Peritoneal Carcinoma

目的观察顺铂(DDP)、氟尿嘧啶(5-Fu)交替腹腔灌注并ECF(表阿霉素、顺铂、5-氟尿嘧啶)方案治疗原发性腹膜癌腹水控制效果及近期临床疗效、不良反应。方法DDP、5-Fu交替腹腔灌注并ECF方案静脉化疗,21天为一周期,共6～8周期,至少4周期评定疗效。结果15例患者,腹水控制率86.6%;总有效率(RR)86.6%,其中完全缓解(CR)26.6%,部分缓解(PR)60%;主要不良反应为Ⅱ～Ⅲ度骨髓抑制。结论顺铂、氟尿嘧啶交替腹腔灌注并ECF方案治疗原发性腹膜癌腹水控制效果好,近期疗效好,不良反应轻,治疗费用低,可作为原发性腹膜癌的一线治疗方案推广。

Objective To observe the ascites control effects and short-term clinical efficacy and toxicity in the treatment of primary peritoneal carcinoma with cisplatin （DDP）, ftuorouracil （5-Fu） alternating ab- dominal perfusion and systemic chemotherapy of ECF （epirubicin, cisplatin, 5- fluorouracil）. Methods DDP,5-Fu alternating intraperitoneal perfusion plus ECF program intravenous chemotherapy, one cycle of 21 days for a total of 6-8 cycles, was evaluate at least after 4 cycles. Results In 15 cases, the ascites control rate was 86. 6%, and the total effective rate （RR） 86. 6%, including complete remission （CR） （26. 6 % ）, and partial remission （PR） （60 %）. The major toxicity wasⅡ-Ⅲ myelosuppression. Conclusion DDP and 5-Fu alternating intraperitoneal perfusion plus ECF in the treatment of primary peritoneal carcinoma has better control of ascites and satisfactory short-term efficacy, slight toxicity light and low- cost. It can be used as first-line treatment programs for primary peritioneal carcinoma.